TY - JOUR
T1 - Immune Checkpoint Inhibitor–Associated AKI
T2 - Debates in Diagnosis, Management, and Rechallenge
AU - Seethapathy, Harish
AU - Herrmann, Sandra M.
AU - Rashidi, Arash
N1 - Publisher Copyright:
© 2023
PY - 2022/11
Y1 - 2022/11
N2 - Immune checkpoint inhibitors (ICIs) are now established treatments for advanced cancer and their use is now ubiquitous. The high upside of ICIs is tempered by their toxicity profile affecting almost every organ, including the kidneys. Although acute interstitial nephritis is the major kidney-related adverse effect of checkpoint inhibitors, other manifestations such as electrolyte abnormalities and renal tubular acidosis have been described. With increasing awareness and recognition of these events, the focus has shifted to non-invasive identification of ICI-acute interstitial nephritis, with sophisticated approaches involving biomarkers and immunologic signatures being studied. Although the management of immune-related adverse events with corticosteroids is straightforward, there now are more data to help guide immunosuppressive regimens, ICI rechallenge, and delineate risk and efficacy in special populations such as individuals on dialysis or those who have received a transplant.
AB - Immune checkpoint inhibitors (ICIs) are now established treatments for advanced cancer and their use is now ubiquitous. The high upside of ICIs is tempered by their toxicity profile affecting almost every organ, including the kidneys. Although acute interstitial nephritis is the major kidney-related adverse effect of checkpoint inhibitors, other manifestations such as electrolyte abnormalities and renal tubular acidosis have been described. With increasing awareness and recognition of these events, the focus has shifted to non-invasive identification of ICI-acute interstitial nephritis, with sophisticated approaches involving biomarkers and immunologic signatures being studied. Although the management of immune-related adverse events with corticosteroids is straightforward, there now are more data to help guide immunosuppressive regimens, ICI rechallenge, and delineate risk and efficacy in special populations such as individuals on dialysis or those who have received a transplant.
KW - Immune-related adverse events
KW - acute interstitial nephritis
KW - acute kidney injury
KW - biomarkers
KW - checkpoint nephrotoxicity
UR - http://www.scopus.com/inward/record.url?scp=85154057700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85154057700&partnerID=8YFLogxK
U2 - 10.1016/j.semnephrol.2023.151346
DO - 10.1016/j.semnephrol.2023.151346
M3 - Review article
C2 - 37137187
AN - SCOPUS:85154057700
SN - 0270-9295
VL - 42
JO - Seminars in nephrology
JF - Seminars in nephrology
IS - 6
M1 - 151346
ER -